Cheri Beasley is well-positioned to win North Carolina’s U.S. Senate seat, with her strong candidacy and record, and a campaign that continues to build unmatched statewide support. Deeply-flawed D.C. Insider Ted Budd’s nomination makes this battleground state even more winnable for Beasley this fall.
Why Cheri is the Candidate Who Can Win:
Cheri’s Story and Record of Service
Cheri’s compelling personal story and record of serving with the values of justice and integrity resonate with voters. As a public defender, judge and Chief Justice of the North Carolina Supreme Court, Cheri worked to uphold the Constitution and partnered with law enforcement to keep communities safe – no matter the politics.
As Chief Justice, Cheri created the first human trafficking court in the state to hold violent offenders accountable and support victims, and she supports new funding to put more, better-trained police officers in communities across the state. Cheri and her husband Curt raised their twin sons here in North Carolina and she has seen how both political parties are part of the problem in Washington.
In the Senate, Cheri will continue to lead with integrity and justice:
- Push for banning members of Congress from trading stocks
- Fight to lower prescription drug costs and expand the Affordable Care Act
- Build a Made-in-America economy that invests in manufacturing, agriculture, clean energy, and other critical industries
- Support skills apprenticeship and training programs to grow in-demand, high-paying jobs
Building a Campaign that Can Win Key 2022 Battleground
The Beasley campaign has built an operation to win in November:
- Polling Shows Race Tied: Recent polling shows this race is tied and winnable for Cheri. Cheri is already coalescing support among Democratic base voters and leading Budd among critical swing groups, including suburban voters and white college-educated voters.
- Competitive Race Requiring GOP to Spend Millions: Washington Republicans know this race is competitive and already are spending more than $1 million on negative attacks — more than against any other Democratic challenger in the country.
- Unmatched Fundraising: Cheri has raised more than $9.6 million and support from all 100 countries – doubling Budd’s fundraising in the same period.
- Engaging Voters Early: The campaign began statewide TV and digital advertising in April, introducing Cheri to voters while Budd remained locked in a divisive primary. And North Carolina Democrats have already launched a coordinated campaign to reach voters directly in every corner of the state.
- Winning in Tough Cycles: Cheri can excite and mobilize voters with her qualified and historic candidacy, and has shown she can win in tough political environments. She has won statewide twice, even in tough political environments like 2014, and in 2020 she outperformed most Democrats on the ballot, including in rural communities.
Budd’s Nomination Makes North Carolina Even More Winnable
A two-term Congressman with a record of hurting North Carolinians, D.C. Insider Ted Budd’s nomination tips this race in Cheri’s favor. Here’s how the GOP primary went for Ted Budd:
- Budd needed more than $12 million in outside spending from D.C. super PAC Club for Growth to make it through the primary – that’s the most this group ever spent for any single candidate.
- Members of Budd’s own party have said that Budd is a “weak general election candidate” and “a bad candidate” who is “wholly owned and operated” by dark money groups like Club for Growth.
- The Washington Post and other outlets reported on his role in “his family’s calamitous involvement” in a bankruptcy case that cost farmers millions of dollars in losses.
- Budd “agreed with the major points” of Senate Republicans’ plan that would raise taxes on 40 percent of North Carolinians.
- He opposed legislation to create jobs, including the bipartisan infrastructure law that North Carolina’s Republican Senators voted for and will strengthen North Carolina highways, bridges, and public transportation.
- Budd voted against a bipartisan plan to lower prescription drug costs at a time when people are struggling with rising costs.